DNA

The funding was led by 180 Degree Capital and included Third Kind Venture Capital, Lateral Capital, the Band of Angels and the Berkeley Angel Network, along with other investors.

“We appreciate the support from our investors to fund the next stage of the growth of our business,” said Denis Kourakin, president and chief executive officer of NGX Bio. “Our platform makes completion of sequencing projects simpler and more affordable for all clients and allows them to scale without the need for capital investment. This funding will allow us to continue our relentless focus on delivering high-quality, rapid and cost-effective sequencing solutions for our customers.”

NGX Bio, founded in 2014, provides on-line access to next-generation sequencing services for clients seeking sequencing of both human and non-human samples globally. The company’s platform matches the sequencing needs of customers with providers who have available sequencing capacity.